News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)



3/8/2012 6:10:54 AM

MALVERN, Penn.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted an Orphan Drug designation to Promedior’s lead drug candidate, PRM-151, for the treatment of idiopathic pulmonary fibrosis (IPF). There are currently no FDA approved treatments for IPF, a progressive, debilitating and fatal disease that affects approximately 200,000 people in Europe and the United States combined.

Read at BioSpace.com

Related News

comments powered by Disqus
Promedior
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES